American International Group Inc. raised its position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) by 7.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,534 shares of the biopharmaceutical company’s stock after buying an additional 1,354 shares during the period. American International Group Inc.’s holdings in Aratana Therapeutics were worth $109,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in PETX. Geneva Advisors LLC boosted its stake in shares of Aratana Therapeutics by 4.1% in the first quarter. Geneva Advisors LLC now owns 77,288 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,044 shares during the period. Ray Gerald L & Associates Ltd. boosted its stake in shares of Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 6,600 shares during the period. Baird Financial Group Inc. boosted its stake in shares of Aratana Therapeutics by 32.0% in the first quarter. Baird Financial Group Inc. now owns 40,758 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 9,880 shares during the period. AQR Capital Management LLC boosted its stake in shares of Aratana Therapeutics by 81.9% in the fourth quarter. AQR Capital Management LLC now owns 65,079 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 29,306 shares during the period. Finally, General American Investors Co. Inc. boosted its stake in shares of Aratana Therapeutics by 8.0% in the first quarter. General American Investors Co. Inc. now owns 524,459 shares of the biopharmaceutical company’s stock worth $2,780,000 after buying an additional 38,991 shares during the period. 67.85% of the stock is owned by institutional investors.

Shares of Aratana Therapeutics, Inc. (PETX) opened at 6.07 on Thursday. The stock’s market cap is $261.02 million. Aratana Therapeutics, Inc. has a 12 month low of $4.97 and a 12 month high of $10.73. The firm’s 50-day moving average is $7.04 and its 200 day moving average is $6.42.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The business had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. During the same quarter in the previous year, the business posted $0.61 earnings per share. The business’s revenue was down 86.4% compared to the same quarter last year. On average, equities analysts predict that Aratana Therapeutics, Inc. will post ($1.04) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/american-international-group-inc-increases-position-in-aratana-therapeutics-inc-nasdaqpetx/1469187.html.

A number of equities research analysts have recently issued reports on the stock. BidaskClub cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Sunday, May 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $10.00.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.